PubMed Health⌕ Search

Biomedical subjects

S D Marlin

Publications and source records attributed to S D Marlin.

24 records · Page 2Linked to original sources

Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites.

Epitopes of herpes simplex virus type 1 (HSV-1) strain KOS glycoprotein gC were identified by using a panel of gC-specific, virus-neutralizing monoclonal antibodies and a series of antigenic variants selected for resistance to neutralization with individual members of the antibody panel. Variants that were resistant to neutralization and expressed an antigenically altered form of gC were designated monoclonal antibody-resistant (mar) mutants. mar mutants were isolated at frequencies of 10(-3) to 10(-5), depending on the antibody used for selection. The epitopes on gC were operationally grouped into antigenic sites by evaluating the patterns of neutralization observed when a panel of 22 antibodies was tested against 22 mar mutants. A minimum of nine epitopes was identified by this process. Three epitopes were assigned to one antigenic site (I), and six were clustered in a second complex site (II) composed of three distinct subsites, IIa, IIb, and IIc. The two antigenic sites were shown to reside in physically distinct domains of the glycoprotein, by radioimmunoprecipitation of truncated forms of gC. These polypeptides lacked portions of the carboxy terminus and ranged in size from approximately one-half that of the wild-type molecule to nearly full size. Antibodies recognizing epitopes in site II immunoprecipitated the entire series of truncated polypeptides and thereby demonstrated that site II resided in the N-terminal half of gC. Antibodies reactive with site I, however, did not immunoprecipitate fragments smaller than at least two-thirds the size of the wild-type polypeptide, suggesting that site I was located in the C-terminal portion. Sites I and II were also shown to be spatially separate on the gC polypeptide by competition enzyme-linked immunosorbent assay with monoclonal antibodies representative of different site I and site II epitopes.

Animals↗

Herpes simplex virus type 1 glycoprotein C-negative mutants exhibit multiple phenotypes, including secretion of truncated glycoproteins.

A virus-neutralizing monoclonal antibody specific for glycoprotein C (gC) of herpes simplex virus type 1 strain KOS was used to select a number of neutralization-resistant mutants. A total of 103 of these mutants also were resistant to neutralization by a pool of gC-specific antibodies and thus were operationally defined as gC-. Analysis of mutant-infected cell mRNA showed that a 2.7-kilobase mRNA, comparable in size to the wild-type gC mRNA, was produced by nearly all mutants. However, six mutants, gC-5, gC-13, gC-21, gC-39, gC-46, and gC-98, did not produce the normal-size gC mRNA but rather synthesized a novel 1.1-kilobase RNA species. These mutants had deletions of 1.6 kilobases in the coding sequence of the gC structural gene, which explains their gC- phenotype. Despite the production of an apparently normal mRNA by the remaining 97 mutants, only 7 mutants produced a detectable gC polypeptide. In contrast to wild-type gC, which is a membrane-bound glycoprotein with an apparent molecular weight of 130,000 (130K), five of these mutants quantitatively secreted proteins of lower molecular weight into the culture medium. These were synLD70 (101K), gC-8 (109K), gC-49 (112K), gC-53 (108K), and gC-85 (106K). The mutant gC-3 secreted a protein that was indistinguishable in molecular weight from wild-type KOS gC. Another mutant, gC-44, produced a gC protein which also was indistinguishable from wild-type gC by molecular weight and which remained cell associated. Pulse-labeling of infected cells in the presence and absence of the glycosylation inhibitor tunicamycin demonstrated that these proteins were glycosylated and provided estimates of the molecular weights of the nonglycosylated primary translation products. The smallest of these proteins was produced by synLD70 and was 48K, about two-thirds the size of the wild-type polypeptide precursor (73K). Physical mapping of the mutations in synLD70 and gC-8 by marker rescue placed these mutations in the middle third of the gC coding sequence. Mapping of the mutations in other gC- mutants, including two in which no protein product was detected, also placed these mutations within or very close to the gC gene. The biochemical and genetic data available on mutants secreting gC gene products suggest that secretion is due to the lack of a functional transmembrane anchor sequence on these mutant glycoproteins.

Animals↗

Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.

The specificity of human natural killer (NK) cells for herpes simplex virus type 1 (HSV-1)-infected WISH cells was examined by using virus-specific antibodies to block NK killing and by using targets infected with virus variants that express antigenically altered cell surface glycoproteins. Fab fragments of human immunoglobulin (Ig) derived from an HSV-1 seropositive individual blocked NK activity against HSV-1-infected cells, whereas Fab fragments from a seronegative individual had no effect. Fab fragments of monoclonal antibodies specific for different epitopes of the HSV-1 glycoproteins gB and gC blocked NK activity, suggesting that NK cells interact directly with viral glycoproteins. In contrast, a control (HSV-unreactive) monoclonal antibody did not block NK activity. Further evidence that the blocking activity was associated with HSV glycoproteins was obtained by showing that: a) gC-specific antibodies did not decrease NK activity against cells infected with an HSV-1 mutant which does not insert gC into infected cell surface membranes; b) gB-specific antibodies did not reduce NK cytotoxicity against target cells infected with HSV-1 in the presence of 2-deoxy-D-glucose (2dG), which prevents cell surface expression of gB; c) HSV-1 glycoprotein-specific antibodies did not alter NK activity against uninfected cells or against K562, an NK-susceptible tumor cell line; and d) a monoclonal antibody reactive with a cell membrane glycolipid markedly reduced NK reactivity against K562 but had little effect on NK reactivity against HSV-1-infected cells, suggesting that NK cells recognize different determinants on the two types of target cells. Analysis of the fine specificity of NK cell recognition of HSV-1 glycoproteins was performed by using target cells infected with antigenic variants of HSV-1 referred to as monoclonal antibody-resistant (mar) mutants. mar mutants are altered in distinct epitopes of gB or gC, resulting in loss of recognition by the selecting virus-neutralizing monoclonal antibody. NK activity was reduced against cells infected with some, but not all, of these variants. Together, these findings demonstrated a positive correlation between expression of HSV-1 glycoproteins gB and gC and susceptibility of HSV-1-infected target cells to NK activity, implicating the viral glycoproteins as cell surface components recognized by NK cells. Moreover, mutations affecting glycoprotein epitopes defined by monoclonal antibodies also influenced the interaction between NK effector cells and HSV-1-infected target cells, suggesting that viral antigenic sites recognized by NK cells overlap with those recognized by anti-HSV-1 antibodies.

Adult↗

Inhibition of glycosylation of herpes simplex virus glycoproteins: identification of antigenic and immunogenic partially glycosylated glycopeptides on the cell surface membrane.

The surface membranes of cells infected with herpes simplex virus type 1 (HSV-1), strain KOS, contain three principal glycoproteins, gC (apparent Mr 129k), gB (apparent Mr 120k), and gD (apparent Mr 58k). Infections carried out in the presence of the glycosylation inhibitor 2-deoxy-D-glucose result in the loss of the mature species with the concurrent appearance of lower-molecular-weight polypeptides which are presumably partially glycosylated forms of the fully processed glycoproteins. Specific immunoprecipitation of radiolabeled cytoplasmic extracts of 2-deoxy-D-glucose-inhibited infections identified partially glycosylated proteins designated DG92, DG88, and DG53, which are antigenically related to the corresponding mature forms gB, gC, and gD. Cell surface radioiodination, in combination with specific immunoprecipitation, revealed that DG88 and DG53 were the principal species transported to the cell surface in 2-deoxy-D-glucose-inhibited infections. DG92 was readily detected in the cytoplasm but not on the plasma membrane. Cells infected with the KOS mutant, syn LD70, did not synthesize glycoprotein gC. In glycosylation-inhibited syn LD70 infections, DG88 was not detected in either the cytoplasm or plasma membrane, demonstrating a genetic relationship between DG88 and gC. Polyclonal and monoclonal antibodies directed against the glycoproteins gC, gB, and gD sensitized infected cells to complement-mediated immune cytolysis. Cells infected in the presence of the inhibitor were sensitized to lysis only by antibody specific for gC and gD. The glycosylation-inhibited cells were insensitive to immunolysis by anti-gB monoclonal antibody. These findings confirm that the glycosylation-deficient forms of gC and gD, but not gB reach the cell surface in the presence of inhibitor and that the inhibitor-induced alterations in glycosylation do not cause a complete loss of antigenicity. Inoculation of mice with syngeneic 3T3 cells infected in the presence or absence of inhibitor-induced cytolytic and neutralizing antibody. A major portion of the cytolytic antibody was directed against gC, but anti-gC antibody appeared to play a minor role in virus neutralization. While the serum induced by the control infected cells contained precipitating antibodies for gC, gB, and gD, the serum derived from mice inoculated with inhibitor-treated infected cells had only weak immunoprecipitating activity against gB. Together, these findings have identified partially glycosylated forms of the major HSV glycoproteins and show that complete glycosylation is not required for transport of some of these partially glycosylated polypeptides to the cell surface. Moreover, complete glycosylation of the glycopeptides is not essential for maintenance of antigenicity or immunogenicity, indicating that at least some determinants recognized by antibodies directed against the mature glycoproteins are not affected by 2-deoxy-D-glucose-induced carbohydrate alterations.

Animals↗

Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies.

Monoclonal antibodies specific for herpes simplex virus type 1 (HSV-1) glycoproteins were used to demonstrate that HSV undergoes mutagen-induced and spontaneous antigenic variation. Hybridomas were produced by polyethylene glycol-mediated fusion of P3-X63-Ag8.653 myeloma cells with spleen cells from BALB/c mice infected with HSV-1 (strain KOS). Hybrid clones were screened for production of HSV-specific neutralizing antibody. The glycoprotein specificities of the antibodies were determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of immunoprecipitates of radiolabeled infected-cell extracts. Seven hybridomas producing antibodies specific for gC, one for gB, and one for gD were characterized. All antibodies neutralized HSV-1 but not HSV-2. Two antibodies, one specific for gB and one specific for gC, were used to select viral variants resistant to neutralization by monoclonal antibody plus complement. Selections were made from untreated and bromodeoxyuridine- and nitrosoguanidine-mutagenized stocks of a plaque-purified isolate of strain KOS. After neutralization with monoclonal antibody plus complement, surviving virus was plaque purified by plating at limiting dilution and tested for resistance to neutralization with the selecting antibody. The frequency of neutralization-resistant antigenic variants selected with monoclonal antibody ranged from 4 X 10(-4) in nonmutagenized stocks to 1 X 10(-2) in mutagenized stocks. Four gC and four gB antigenic variants were isolated. Two variants resistant to neutralization by gC-specific antibodies failed to express gC, accounting for their resistant phenotype. The two other gC antigenic variants and the four gB variants expressed antigenically altered glycoproteins and were designated monoclonal-antibody-resistant, mar, mutants. The two mar C mutants were tested for resistance to neutralization with a panel of seven gC-specific monoclonal antibodies. The resulting patterns of resistance provided evidence for at least two antigenic sites on glycoprotein gC.

Antibodies, Monoclonal↗

Physical mapping of the mutation in an antigenic variant of herpes simplex virus type 1 by use of an immunoreactive plaque assay.

Two mutations affecting herpes simplex virus type 1 glycoprotein B were mapped by marker rescue using cloned sequences of wild-type herpes simplex virus type 1 strain KOS DNA. One mutant, tsB5, is a temperature-sensitive mutant which does not express mature, functional glycoprotein B at the nonpermissive temperature. The other mutant, marB1.1, expresses an antigenic variant of glycoprotein B and was selected for resistance to neutralization by a monoclonal antibody. The mutation in tsB5 mapped to a 1.2-kilobase segment of the herpes simplex virus type 1 genome between coordinates 0.361 and 0.368, whereas the mutation in marB1.1 mapped to a 1.6-kilobase segment between coordinates 0.350 and 0.361. An in situ enzyme immunoassay was used to detect plaques of recombinant wild-type virus among the progeny of transfections with mutant marB1.1 DNA and wild-type DNA fragments.

Antigens, Viral↗